Step by Step


ABIM MOC Activity ID

11/9/2021 - Medical Grand Rounds: Lung Cancer in the 21st Century





Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Overview, Screening and Early Detection
Presented by: David Wilson, MD, MPH

Lung Cancer: Hitting the Target
Presented by: Antoinette Wozniak, MD

Taking the break off antitumor immunity - a new age in lung cancer treatment!
Presented by: Taofeek Owonikoko, MD, PhD

Educational Objectives:

Upon completion of this activity, participants should be able to:
  • Improve safeguards for toxicity of immunotherapy
  • Apply recommended guidelines for the use of immunotherapy in lung cancer
  • Improve patient outcomes through appropriate use of approved immunotherapy drugs in lung cancer
  • Explain the evolution of targeted therapy in non-small cell lung cancer
  • Describe the importance of molecular profiling in the treatment of non-small-cell lung cancer
  • Discuss the current actionable targets in non-small-cell lung cancer

Joint Accreditation Statement - Note: This Accreditation Statement Supersedes All Other Statements:

    Joint Accreditation Statement

    In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit[s]™. Physicians should only claim credit commensurate with the extent of their participation in the activity. This educational activity is approved for 1.0 contact hours.

    Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Suggested Additional Reading:

  1. Lynch TJ, Bell DW, Sordella R, et al. N Engl J Med. 2004;350:2129-2139.
  2. Marmaremis ME, Langer CJ. Clin Lung Cancer. 2020;21(5):395-405.
  3. Shaw AT, Engelman JA. J Clin Oncol. 2013;31(8):1105-1111.
  4. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28. PMID: 31562796
  5. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. Reck M, Rodríguez-Abreu D, Robinson AG, et al; KEYNOTE-024 Investigators. N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8. PMID: 27718847
  6. Hong DS, Fakih MG, Strickler JH, et al. N Engl J Med. 2020;383(13):1207-1217.

Antoinette Wozniak, MD — Professor of Medicine, Division of Hematology/Oncology
Associate Director of Clinical Research, UPMC Hillman Cancer Center
Director, Lung Cancer Disease Unit
Co-Director, UPMC Lung Cancer Center of Excellence
University of Pittsburgh School of Medicine
No relationships with industry relevant to the content of this educational activity have been disclosed.
David Wilson, MD, MPH — Associate Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine
Associate Professor of Cardiothoracic Surgery, and Clinical & Translational Science
Associate Director, Lung Cancer Center, Hillman Cancer Center
Director, Georgia Cooper Memorial Lung Nodule/Lung Cancer Research Registry
University of Pittsburgh School of Medicine
Dr. Wilson is an Advisory Board member and shareholder in Savicell™ Ltd.
Taofeek Owonikoko, MD, PhD — Professor of Medicine and Division Chief, Hematology/Oncology
Stanley Marks / OHA Chair in Oncology Leadership
Associate Director for Translational Research, UPMC Hillman Cancer Center
Co-Leader, Cancer Therapeutics Program, UPMC Hillman Cancer Center
University of Pittsburgh School of Medicine

No relationships with industry relevant to the content of this educational activity have been disclosed.
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity is approved for AMA PRA Category 1 Credit™

The University of Pittsburgh is an affirmative action, equal opportunity institution.